Inclusion Criteria:

- Patients must have a Karnofsky performance status of >= 60%

- Patients must have histological confirmation of colorectal carcinoma

- Patients must have colorectal tumors that produce carcinoembryonic antigen (CEA) as
documented by either immunohistochemistry or by an elevated serum CEA

- Patients will be enrolled on this trial after resection of hepatic metastases
combined with FOLFIRI or FOLFOX [+/- Bevacizumab], or XELOX; patients may have
received a maximum of 12 cycles of FOLFIRI or FOLFOX [+/- Bevacizumab], or XELOX,
which includes chemotherapy prior to and post hepatic resection

- Prior radiotherapy, immunotherapy, or chemotherapy must have been completed between
4-12 weeks prior to patient entry on this study and patients must have recovered from
all expected acute side effects of the prior therapy

- Hemoglobin >= 10 gm %; patients may be transfused to reach a hemoglobin >= 10 gm %

- White blood cell (WBC) >= 4000/uL

- Absolute neutrophil count (ANC) >= 1,500/mm^3

- Platelets >= 150,000/ul

- Patients may have history of prior malignancy for which the patient has been
disease-free for five years; basal or squamous cell skin cancers or carcinoma in situ
of the cervix are allowed regardless of diagnosis date

- Patients must have no prior history of radiation therapy to the liver (includes 90Y
microsphere therapy)

- Patients must have a total bilirubin =< 1.5 mg/dL

- Serum creatinine of =< 1.5 x upper limit of normal (ULN)

- Patients must have had < 40% liver resected at the close of completion of the hepatic
resection; this will be verified retrospectively

- Serum human immunodeficiency virus (HIV) testing and hepatitis B surface antigen and
hepatitis C antibody testing must be negative

- Women of childbearing potential must have a negative serum pregnancy test prior to
entry and while on study must be practicing an effective form of contraception

- If a patient has previously received murine or chimeric antibody, then serum
anti-antibody testing must be negative

- Computed tomography (CT) scan restaging done prior to RIT must demonstrate no
evidence of progressive disease

- The patient must be seen in consultation by the radiation oncologist who will be
administering the radiolabeled antibody therapy and must be informed of the potential
risks and side effects of the therapy, and informed consent must be documented in the
consultation note

Exclusion Criteria:

- Patients that have received radiation therapy to greater than 50% of their bone
marrow

- Patients with any nonmalignant intercurrent illness (example cardiovascular,
pulmonary, or central nervous system disease) which is either poorly controlled with
currently available treatment or which is of such severity that the investigators
deem it unwise to enter the patient on protocol shall be ineligible

- Chronic active hepatitis, cirrhosis, or chemotherapy steatohepatitis